NASDAQ:FLGT - Fulgent Genetics Stock Price, News & Analysis

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Fulgent Genetics Inc (NASDAQ:FLGT) issued its quarterly earnings data on Monday, August, 5th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.06. The company had revenue of $8.42 million for the quarter, compared to analyst estimates of $6.42 million. Fulgent Genetics had a negative return on equity of 4.71% and a negative net margin of 12.38%. View Fulgent Genetics' Earnings History.

Fulgent Genetics is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Fulgent Genetics.

2 Wall Street analysts have issued 12 month price targets for Fulgent Genetics' shares. Their predictions range from $9.50 to $9.50. On average, they expect Fulgent Genetics' share price to reach $9.50 in the next year. This suggests that the stock has a possible downside of 16.2%. View Analyst Price Targets for Fulgent Genetics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Fulgent Genetics.

News articles about FLGT stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Fulgent Genetics earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Fulgent Genetics.

Fulgent Genetics saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 25,000 shares, an increase of 410.2% from the July 31st total of 4,900 shares. Based on an average daily volume of 40,700 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.4% of the company's stock are sold short. View Fulgent Genetics' Current Options Chain.

Some companies that are related to Fulgent Genetics include RadNet (RDNT), Personalis (PSNL), Castle Biosciences (CSTL), Celcuity (CELC), Enzo Biochem (ENZ), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX), CBA Florida (CBAI), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), OpGen (OPGN) and Aeon Global Health (AGHC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include Crispr Therapeutics (CRSP), Zynerba Pharmaceuticals (ZYNE), Baidu (BIDU), Catalyst Pharmaceuticals (CPRX), Intellia Therapeutics (NTLA), Canopy Growth (CGC), Corbus Pharmaceuticals (CRBP), DexCom (DXCM), Fate Therapeutics (FATE) and Myriad Genetics (MYGN).

(FLGT) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Fulgent Genetics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Mutual Advisors LLC (0.95%), River & Mercantile Asset Management LLP (0.84%), River & Mercantile Asset Management LLP (0.84%) and BlackRock Inc. (0.09%). Company insiders that own Fulgent Genetics stock include Ming Hsieh and Paul Kim. View Institutional Ownership Trends for Fulgent Genetics.

FLGT stock was sold by a variety of institutional investors in the last quarter, including Mutual Advisors LLC. View Insider Buying and Selling for Fulgent Genetics.

FLGT stock was acquired by a variety of institutional investors in the last quarter, including River & Mercantile Asset Management LLP, River & Mercantile Asset Management LLP and BlackRock Inc.. View Insider Buying and Selling for Fulgent Genetics.

Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FLGT stock can currently be purchased for approximately $11.33.

Fulgent Genetics has a market capitalization of $209.45 million and generates $21.36 million in revenue each year. The company earns $-5,610,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Fulgent Genetics employs 123 workers across the globe.View Additional Information About Fulgent Genetics.

The official website for Fulgent Genetics is http://www.fulgentgenetics.com/.

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE SUITE 205, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected]